Derek Archila
Stock Analyst at Wells Fargo
(4.49)
# 274
Out of 5,241 analysts
214
Total ratings
57.58%
Success rate
18.03%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Maintains: Equal-Weight | $2 → $4 | $3.31 | +20.85% | 12 | May 15, 2026 | |
| ALMS Alumis | Maintains: Overweight | $49 → $51 | $22.87 | +123.00% | 3 | May 15, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $38 → $54 | $31.34 | +72.30% | 5 | May 13, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,247 → $1,260 | $799.32 | +57.63% | 17 | May 8, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $330 → $326 | $240.43 | +35.59% | 17 | May 8, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $143 → $144 | $90.52 | +59.08% | 10 | May 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $376 → $377 | $286.98 | +31.37% | 3 | May 1, 2026 | |
| SLNO Soleno Therapeutics | Downgrades: Equal-Weight | $110 → $53 | $53.01 | -0.02% | 5 | Apr 17, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $29 → $28 | $15.86 | +76.60% | 9 | Apr 9, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $29 → $20 | $16.82 | +18.91% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $2.03 | +146.31% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $29 | $18.15 | +59.78% | 10 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $48 | $26.95 | +78.11% | 6 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $78 → $79 | $66.86 | +18.16% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $98 | $66.13 | +48.19% | 3 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $101 | $95.31 | +5.97% | 13 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $9.49 | +247.73% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $82.21 | +41.10% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $8.15 | +206.75% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.21 | +418.23% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $9.08 | +65.20% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $63.15 | +28.27% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $50.13 | -40.16% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $3.56 | +180.90% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.50 | +98.41% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $38.97 | -23.02% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $4.05 | +23.46% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $6.30 | +138.10% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $23.93 | -41.50% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $27.49 | +63.70% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.12 | +541.03% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.44 | +230.88% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $92.32 | -55.59% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.51 | +1,003.07% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $19.65 | +205.34% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $6.28 | +361.78% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $0.85 | +5,782.35% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $28.78 | +77.21% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $10.61 | +729.41% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $22.64 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $34.29 | - | 2 | Aug 3, 2017 |
Cabaletta Bio
May 15, 2026
Maintains: Equal-Weight
Price Target: $2 → $4
Current: $3.31
Upside: +20.85%
Alumis
May 15, 2026
Maintains: Overweight
Price Target: $49 → $51
Current: $22.87
Upside: +123.00%
Celldex Therapeutics
May 13, 2026
Maintains: Overweight
Price Target: $38 → $54
Current: $31.34
Upside: +72.30%
argenx SE
May 8, 2026
Maintains: Overweight
Price Target: $1,247 → $1,260
Current: $799.32
Upside: +57.63%
Ascendis Pharma
May 8, 2026
Maintains: Overweight
Price Target: $330 → $326
Current: $240.43
Upside: +35.59%
Rhythm Pharmaceuticals
May 6, 2026
Maintains: Overweight
Price Target: $143 → $144
Current: $90.52
Upside: +59.08%
Alnylam Pharmaceuticals
May 1, 2026
Maintains: Equal-Weight
Price Target: $376 → $377
Current: $286.98
Upside: +31.37%
Soleno Therapeutics
Apr 17, 2026
Downgrades: Equal-Weight
Price Target: $110 → $53
Current: $53.01
Upside: -0.02%
Nurix Therapeutics
Apr 9, 2026
Maintains: Overweight
Price Target: $29 → $28
Current: $15.86
Upside: +76.60%
Viridian Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $29 → $20
Current: $16.82
Upside: +18.91%
Mar 19, 2026
Initiates: Overweight
Price Target: $5
Current: $2.03
Upside: +146.31%
Mar 18, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $18.15
Upside: +59.78%
Mar 3, 2026
Maintains: Overweight
Price Target: $28 → $48
Current: $26.95
Upside: +78.11%
Mar 2, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $66.86
Upside: +18.16%
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $66.13
Upside: +48.19%
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $95.31
Upside: +5.97%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $9.49
Upside: +247.73%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $82.21
Upside: +41.10%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $8.15
Upside: +206.75%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.21
Upside: +418.23%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $9.08
Upside: +65.20%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $63.15
Upside: +28.27%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $50.13
Upside: -40.16%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $3.56
Upside: +180.90%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.50
Upside: +98.41%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $38.97
Upside: -23.02%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $4.05
Upside: +23.46%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $6.30
Upside: +138.10%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $23.93
Upside: -41.50%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $27.49
Upside: +63.70%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.12
Upside: +541.03%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.44
Upside: +230.88%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $92.32
Upside: -55.59%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.51
Upside: +1,003.07%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $19.65
Upside: +205.34%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $6.28
Upside: +361.78%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $0.85
Upside: +5,782.35%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $28.78
Upside: +77.21%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $10.61
Upside: +729.41%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $22.64
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $34.29
Upside: -